Periodontitis: Diabetes Complication?
Studies have suggested that periodontal therapy may improve glycemic control, although the largest RCT to date has questioned those findings.
Read More
Insulin Sensitivity with Dapagliflozin: Impact of ZAG
Zinc-Α2-glycoprotein is an adipokine thought to be involved in promoting lipolysis, as well as modulating insulin sensitivity.
Bariatric Surgery in Diabetes Management
Is it time to add bariatric/metabolic surgery to diabetes treatment guidelines? What criteria should be used to select candidates for surgery?
Adding SGLT2 Inhibitors to Insulin
Did adding an SGLT2 inhibitor improve glycemic control in patients with type 2 diabetes? A recent meta-analysis explores this question.
Triple Therapy: Dapagliflozin, Saxagliptin, Metformin
The study began with patients receiving saxagliptin plus metformin. Then, patients with glycemic control were randomized to placebo or dapagliflozin.
Skin Autofluorescence: Noninvasive Diabetes Tool?
Skin autofluorescence may be a new, noninvasive technique to assess risk of cardiovascular and renal impairment in type 1 diabetes.
The Renin-Atherosclerosis Link in Diabetes
Researchers analyzed renin and markers of inflammation and fibrous components from plaques of patients who had undergone carotid endarterectomy.
Impact of Fasting Triglycerides on CV & Diabetes Risk
What impact, if any, do fasting triglycerides have on cardiovascular and diabetes risk in patients with prediabetes?
Sleep Disturbances: Type 2 Diabetes Risk?
Sleep disturbances commonly co-occur with diabetes, yet they are not included in screening recommendations for type 2 diabetes. Should they be?
Canagliflozin Added to Insulin: a Japanese Study
In patients with poorly controlled T2DM despite insulin, diet, & exercise therapies, was the SGLT2 inhibitor well tolerated and effective?
HbA1c and Weight: Canaglioflozin vs Sitaglitpin
A post hoc analysis pooled data from two randomized controlled phase 3 studies to compare the SGLT2i to the DPP-4i as adjunctive treatment.
Effects of Pioglitazone on CV Outcome, Diabetes
Could pioglitazone be the first anti-diabetes agent to prevent diabetes progression and improve cardiovascular outcomes?
Celiac Disease & Diabetes: Who’s Most at Risk?
A large study of celiac disease looked at prevalence of T1DM and T2DM, and health risks associated with having both celiac disease and diabetes.
High Risk Periods for Hypoglycemia
Researchers explored seasonal variations in hypoglycemia and compared differences in type 1 diabetes and type 2 diabetes.
Empagliflozin Linked to Improved Albuminuria
SGLT2 inhibition has been shown to preserve renal function and decrease albuminuria in animal models, but do these results apply to humans?
Do SGLT2 Inhibitors Really Increase Fracture Risk?
A new meta-analysis delved further into the topic of fracture risk with SGLT2 inhibitors. Was new evidence uncovered?
Is Butter Better for Long-Term Health?
Does butter deserve its bad rap? A meta-analysis examines butter consumption and type 2 diabetes, as well as mortality and cardiovascular disease.
PAH Complicates Post-MI RV Dysfunction
A new study assessed the poorly understood impact of pulmonary hypertension on mortality after myocardial infarction.
The Mediterranean Diet: Sailing the Wine Dark Sea
The Mediterranean diet has been linked to decreased risk of metabolic syndrome, diabetes, and CV events, but there is also criticism of these studies.
Human Islet Transplant in Type 1 Diabetes
What were the pros and cons of a transplanted human pancreatic islets product in patients with type 1 diabetes and impaired awareness of hypoglycemia?
New HF Guidelines from the ESC
This short slide show highlights new drugs now recommended, a new HF category, and recommendations for optimizing treatment.
Fat Cell Function with Dapagliflozin
Researchers investigated changes in biomarker levels of obese patients with type 2 diabetes taking dapagliflozin.
Fun in the Sun: Vitamin D and Diabetes
What role, if any, does vitamin D play in the development of diabetes or diabetic complications?
Cardiovascular Risks with Insulins
Investigators examined cardiovascular risk with the new basal insulin peglispro compared to insulin glargine or NPH in diabetic patients.
Canagliflozin Plus Metformin in Type 2 Diabetes
Investigators compared initial therapy with canagliflozin plus metformin to metformin monotherapy in drug naïve type 2 diabetes patients.
SGLT2 Inhibitors or DPP-4 Inhibitors with Insulin
As adjunctive therapy with insulin in poorly controlled type 2 diabetes, which drugs proved more effective – SGLT2 inhibitors or DPP-4 inhibitors?
Gut Micriobiome May Impact Diabetes Development
Changes in the composition of the gut microbiome may contribute to the development of anti-islet autoimmunity, according to the BABYDIET study.
Artificial Pancreas: the Race Is On
Several trials are due to be completed this year, bringing the hope that at least one artificial pancreas system will come to market in 2017.
3-Question Quiz on PAH
What drug has shown survival benefit greater than 3 months in high-risk PAH patients? Select your answer and move to the next question.
Cardiovascular Safety of DPP-4 Inhibitors
To address conflicting reports about the cardiovascular safety of DPP-4 inhibitors, researchers performed a large retrospective cohort study.